Conclusions
HCC
HEPATOCELLULAR CARCINOMA
Combining RFA with anti‐PD‐1 showed improved RFS and was deemed safe for patients with recurrent HCC who had previously undergone RFA treatment alone.Radiofrequency ablation (RFA) combined with toripalimab (anti‐PD‐1) is effective and safe in the treatment of recurrent hepatocellular carcinoma (HCC). Short‐term anti‐PD‐1 in combination with RFA may improve patient prognosis in patients with recurrent HCC.
Zhenyu Wen, Junxiao Wang, and Bo Tu contributed equally to this article.